饮品会引发失眠、心悸？股价大跌！霸王茶姬回应质疑

Core Viewpoint - Recent concerns regarding caffeine content in Bawang Chaji's beverages have led to discussions about potential health effects, impacting the company's stock performance significantly since its NASDAQ listing in April 2023 [1][2]. Financial Performance - For Q3 2025, Bawang Chaji reported a net revenue of 3.208 billion yuan, a year-on-year decline of 9.4%, and a net profit attributable to shareholders of 394 million yuan, down 35.8% year-on-year. The net profit margin decreased to 12.4% from 18.3% in the same period last year [2]. - In the first three quarters of 2025, the company achieved a net revenue of 9.933 billion yuan, reflecting a year-on-year growth of 9.5%, while the net profit attributable to shareholders was 1.107 billion yuan, down 37.6% year-on-year. Despite achieving profitability for 11 consecutive quarters, the net profit has declined for two consecutive quarters [2]. Company Response - Bawang Chaji addressed the concerns about caffeine levels, stating that the caffeine content in their tea drinks is comparable to that of a latte and significantly lower than that of an Americano. The company emphasized the presence of various beneficial compounds in tea, which contribute to its unique flavor and health benefits [2].